Mazisotine
Appearance
| Clinical data | |
|---|---|
| Other names | LY3556050, CNTX-0290 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C16H23N3O2 |
| Molar mass | 289.379 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Mazisotine (LY3556050, CNTX-0290) is a chemical compound which acts as an agonist at somatostatin receptor 4. It has analgesic effects and has been researched for the treatment of pain associated with arthritis and neuropathic pain. It was not pursued for human medical use following disappointing results in Phase II clinical trials, but continues to be used in scientific research.[1][2]
See also
[edit]References
[edit]- ↑ Stevens R, Corradini L, Doods H (April 2019). "Preclinical Evaluation of Human Somatostatin Receptor 4 (hSSTR4) Agonist CNTX-0290 for Mixed Pain Conditions". The Journal of Pain. 20 (4): S73. doi:10.1016/j.jpain.2019.02.092.
- ↑ Nguyen TH, Saito T, Chang W, Navarro A, Davies HM (March 2026). "Diastereoselective Cyclopropanation with Secondary Diazoacetamides to Access endo-Azabicyclo[3.1.0]hexane-6-carboxamides". Organic Letters. 28 (9): 3063–3067. doi:10.1021/acs.orglett.6c00392. PMC 12973298. PMID 41729728.